The rise of a new GABA pharmacology.
Möhler
Hanns
H
Institute of Pharmacology, University of Zurich and Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH) Zurich, Winterthurerstr. 190, CH-8057 Zurich, Switzerland. mohler@pharma.unizh.ch
D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use; D001569:Benzodiazepines / Q000819:agonists / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000494:pharmacology; D026261:Diazepam Binding Inhibitor / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D018682:GABA Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006993:Hypnotics and Sedatives / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology; D016584:Panic Disorder / Q000188:drug therapy / Q000503:physiopathology; D011963:Receptors, GABA-A / Q000187:drug effects* / Q000235:genetics / Q000502:physiology*; D000091042:Reelin Protein; D005680:gamma-Aminobutyric Acid / Q000502:physiology*
D000700:Analgesics; D026261:Diazepam Binding Inhibitor; D018682:GABA Agents; D006993:Hypnotics and Sedatives; D011963:Receptors, GABA-A; D000091042:Reelin Protein; D001569:Benzodiazepines; D005680:gamma-Aminobutyric Acid; C000717127:RELN protein, human